TY - JOUR
T1 - Antipsychotic-induced weight gain and therapeutic response
T2 - A differential association
AU - Czobor, Pál
AU - Volavka, Jan
AU - Sheitman, Brian
AU - Lindenmayer, Jean Pierre
AU - Citrome, Leslie
AU - McEvoy, Joseph
AU - Cooper, Thomas B.
AU - Chakos, Miranda
AU - Lieberman, Jeffrey A.
PY - 2002
Y1 - 2002
N2 - This study investigated the association between antipsychotic-induced weight gain and therapeutic response to haloperidol and three commonly used atypical neuroleptic medications in schizophrenia and schizoaffective disorder. The subjects were 151 patients enrolled in a double-blind experiment with a duration of 14 weeks comparing the therapeutic efficacy of haloperidol (n = 36), clozapine (n = 38), olanzapine (n = 38), and risperidone (n = 39). Absolute and relative (%) gain in body weight and body mass index (BMI) was determined for the entire duration of the double-blind treatment period; therapeutic response was assessed by the total score and the individual subscales of the Positive and Negative Symptom Scale. Compared with the pretreatment baseline, results indicated that for olanzapine and clozapine, therapeutic response was closely related to an absolute and relative gain in weight and to a gain in BMI. No association between weight gain and therapeutic response was found for risperidone and haloperidol. These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain.
AB - This study investigated the association between antipsychotic-induced weight gain and therapeutic response to haloperidol and three commonly used atypical neuroleptic medications in schizophrenia and schizoaffective disorder. The subjects were 151 patients enrolled in a double-blind experiment with a duration of 14 weeks comparing the therapeutic efficacy of haloperidol (n = 36), clozapine (n = 38), olanzapine (n = 38), and risperidone (n = 39). Absolute and relative (%) gain in body weight and body mass index (BMI) was determined for the entire duration of the double-blind treatment period; therapeutic response was assessed by the total score and the individual subscales of the Positive and Negative Symptom Scale. Compared with the pretreatment baseline, results indicated that for olanzapine and clozapine, therapeutic response was closely related to an absolute and relative gain in weight and to a gain in BMI. No association between weight gain and therapeutic response was found for risperidone and haloperidol. These findings suggest that patients who are likely to have the maximal benefits of olanzapine or clozapine treatment for symptom alleviation are at the highest risk of a clinically significant increase in weight gain.
UR - http://www.scopus.com/inward/record.url?scp=0036115924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036115924&partnerID=8YFLogxK
U2 - 10.1097/00004714-200206000-00003
DO - 10.1097/00004714-200206000-00003
M3 - Article
C2 - 12006893
AN - SCOPUS:0036115924
SN - 0271-0749
VL - 22
SP - 244
EP - 251
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 3
ER -